ÂÜÀòÂÒÂ×

Steve has more than thirty-five years’ experience in the biopharmaceutical industry including work for The Immune Tolerance Institute, The Regents of the University of California, The World Bank and BIO Ventures for Global Health. In addition, Steve has previously advised on psychedelic therapies research and clinical trial designs.

He has held senior executive positions with Sequential, Inc. and Inhale Therapeutic Systems, Inc., (now Nektar Therapeutics, Inc.), where he helped the company grow to over 700 employees and raised more than $700 million in investment capital. Steve and Drs. Freeman and Glick co-founded Savant HWP, Inc., in 2009 to advance 18-MC to clinical trials. He is a graduate of Golden Gate University, School of Law and the University of California, Berkeley.